Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout

Core Viewpoint - Gilead Sciences has agreed to acquire the remaining shares of Arcellx, valuing the deal at $7.8 billion, leading to a significant increase in Arcellx's share price towards a new record [1] Company Summary - Gilead Sciences is expanding its portfolio by purchasing the remaining equity of Arcellx, a biotechnology company, indicating a strategic move to enhance its market position [1] - Arcellx's shares experienced a notable surge in early trading, reflecting positive investor sentiment following the acquisition announcement [1]